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Abstract
A critique of the recommendation that skin snips be used for post-MDA surveillance of formerly endemic
onchocerciasis areas is provided. After considering several fundamental aspects of the use of this methodology
within the context of prolonged mass distribution of ivermectin, we argue that skin-snipping has no value for
monitoring onchocerciasis elimination programs.
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Letter to the Editor
We read with interest the recent article by Bottomley
et al. [1] and were surprised that the authors concluded
that skin snips have utilitarian value in evaluating the ef-
ficacy of onchocerciasis elimination programs three
years after final mass drug administration (MDA). We
strongly disagree that skin snips would have any prac-
tical utility in this or any other operational scenario in
assessing whether to stop MDA or in post MDA trans-
mission elimination monitoring. We discuss here four
key concerns that were not addressed in the paper that
led the authors to this erroneous conclusion.
1. Conflicting assumptions in the use of the over
dispersed distribution model. The entire paper rests
on the single key assumption that the over dispersed
model is an appropriate representation for the number
of microfilariae to be found in skin snips. A Poisson
model is first put forward by the authors: “If microfilar-
iae are randomly distributed in the skin, then we can use
the Poisson distribution to calculate the sensitivity dir-
ectly from the density of microfilariae.” There is no valid
reason for this assumption except possibly for the ease
of using mathematical derivations that are familiar to
the authors. Later, the authors change their assertion,“-
However, microfilariae are unlikely to be randomly
distributed in the skin (e.g., the density may depend on
the distribution of fertile worms in the body). If the distribu-
tion is non-random because microfilariae occur in
“clumps”, then this will affect the sensitivity of skin snips be-
cause the chance that a snip contains no microfilariae is in-
creased. To allow for this, we can use the negative binomial
model rather than the Poisson to model the distribution of
the microfilariae in the skin”. The replacement of the
Poisson model by the negative binomial model is gener-
ally done because it is believed that the data is subject to
over dispersion. A critical observation made by Bottom-
ley et al. [1] is that the chances that a skin snip contains
no microfilariae are increased. It would seem reasonable
that as an elimination program proceeds and the num-
ber of microfilariae decreases, that large numbers of zero
snips will be detected in persons actually infected (and
infectious to flies; see, for example, Davies et al. [2]).
Another issue not discussed but germane to the au-
thors’ assumptions is that of the “zero inflation problem”
that occurs as the number of microfilarial positive indi-
viduals in a community decreases. If one assumes that
microfilariae are not uniformly distributed in the skin,
there is the possibility that none are found due to where
the snip is taken even though the person is infected or,
alternatively, a snip is negative because the person is ac-
tually not infected. To compensate for this, additional
statistical measures are required, i.e., using a mixture
distribution of the Poisson/Negative Binomial and a
“point” random variable at zero [3, 4].
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2. Lack of sensitivity. Skin-snipping is a relatively in-
sensitive method for use following long-term MDA. In-
deed, when compared for accuracy (as evaluated by a
more highly sensitive method, e.g., PCR), Thiele et al. [5]
noted that skin snip microscopy demonstrated an insuf-
ficient sensitivity for reliable programmatic monitoring.
This concept was addressed in the most recent World
Health Organization (WHO) Verification Guidelines [6]
that concluded that skin snip sensitivity was about 20%
in populations with low disease prevalence. The Guide-
lines concluded that “Parasitological evaluation by skin
snip microscopy … can be used to monitor progress dur-
ing the first (treatment) phase of onchocerciasis elimin-
ation programmes, but not to verify (bold added)
elimination”.
3. Community-wide resistance to skin-snipping.
Skin-snipping is often painful and not well tolerated by a
sizeable segment of the target population. Bottomley et
al. [1] cite three papers in which population sampling
was complicated by rejection of skin-snipping, yet the
authors fail to mention this in their paper. For example,
Ozoh et al. [7] stated that “… the procedure [skin-snip-
ping] is invasive and may cause secondary bacterial or
viral infections. Even rural people are well informed
about the dangers of human immunodeficiency virus
transmission resulting from invasive procedures and are
now likely to reject skin snipping.” Resurrecting its use
after a 3–5 year hiatus of non-treatment would most likely
be unacceptable on a broad front. This phenomenon has
already occurred repeatedly in several large community-
wide studies and is documented in two more papers cited
by the authors in which high refusal rates of participants
available for skin-snipping were common place. In the
large Mali/Senegal study, 40% of participants did not par-
ticipate 20–22 months after the last Mectizan treatment,
i.e., 22% were absent from the village at the time of exam-
ination and 28% refused to be examined [8]. In at least six
cases, entire villages refused to participate in post MDA
surveillance activities involving skin snips [9]. Further,
given these precedents, to double the number of snips per
person (four instead of two) in order to increase the sensi-
tivity of the model (as recommended by Bottomley et al.
[1]) would be a non-starter in virtually every MDA post-
surveillance setting.
4. Sample sizes required for statistical confidence
obviate the usefulness of skin-snipping. To state with
95% confidence that an infection rate is below 1%,
roughly 300 people need to be examined and all must be
found to be negative. However, this assumes the assay
being used has 100% sensitivity. To a first approxima-
tion, the sensitivity of the assay is inversely proportional
to the number that need to be screened. So if the skin
snip assay is assigned a 20% sensitivity, the need to sam-
ple 300 people at 100% sensitivity translates to needing
to examine 1500 people. Most onchocerciasis endemic
communities targeted for MDA are not that large, which
means in many cases everyone in each village would
have to be snipped. As noted above, broad refusals
would likely prevent this from being realized. Further-
more, even if it were possible to snip everyone in the
community, an assay with a sensitivity of 20% would
yield a false negative result 80% of the time. Simple
probability calculations reveal that if it were possible to
sample everyone in a community of 1000 individuals
with a skin snip assay with a 20% sensitivity and all were
found to be negative one could still not determine with
95% confidence that the actual prevalence in the com-
munity was 1% or less. This is because if there were 10
positive individuals in a community of 1000 people, the
skin-snip probability that all these would be falsely de-
clared negative is greater than 10%. Statistical confidence
would be further skewed if we assume that persons re-
fusing skin snipping are more likely to have refused
MDA (increasing the likelihood that they would be mf
positive).
In conclusions, there are several places where skin
snips might be useful on a limited basis. One is during a
drug trial where demonstration of direct action against
microfilariae may be helpful. Another is for PCR con-
firmation of a suspected patent infection in a person
who is Ov16 positive, as noted in the WHO Guidelines.
Regardless, given these core mitigating factors noted
above, we believe that Bottomley et al. [1] erred in call-
ing for the use of skin-snipping as a method to deter-
mine whether to stop MDA and as a post-MDA
surveillance procedure. The 2016 WHO Guidelines for
the verification of elimination of onchocerciasis state
emphatically that the use of skin snips is to be avoided
as a means to determine whether or not to stop MDA,
and to monitor post-MDA status as a lead up to verifica-
tion of interruption of transmission. Entomological as-
sessments, supplemented with serological testing, as
currently recommended by WHO, is by far the best
available approach for informing these critical decisions.
Country program managers must be made aware of the
extreme lack of usefulness of skin snips in assessing the
elimination of Onchocerca volvulus.
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